Cita APA (7a ed.)

S, S., D, S., A, M., NA, R., R, K., CF, V., . . . AS, I. (2021). Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. Dove Medical Press.

Cita Chicago Style (17a ed.)

S, Shukla, et al. Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. Dove Medical Press, 2021.

Cita MLA (8a ed.)

S, Shukla, et al. Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. Dove Medical Press, 2021.